Strong Potential AheadSeveral New Developments Send Signal
Four Company Developments Have Strong Potential
A successful response to the DOD's RFP and further development of Protectan CBLB502, which the Company forecasts to generate revenues in 2008
The launch of additional Phase II clinical trials for Curaxin CBLC102
The progress of their potential stem cell applications from research, to clinical development
The movement of their radiation protection compounds into human studies, in new therapeutic areas, such as supportive care for cancer and acute organ failure.